193 related articles for article (PubMed ID: 23665979)
61. Comparison of intravitreal ziv-aflibercept and bevacizumab monotherapy in treatment-naive polypoidal choroidal vasculopathy.
Singh SR; Sahoo NK; Goud NR; Chhablani J
Indian J Ophthalmol; 2019 Jul; 67(7):1114-1118. PubMed ID: 31238423
[TBL] [Abstract][Full Text] [Related]
62. Two-year results of photodynamic therapy combined with intravitreal anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy.
Kim M; Kim K; Kim DG; Yu SY; Kwak HW
Ophthalmologica; 2011; 226(4):205-13. PubMed ID: 21893965
[TBL] [Abstract][Full Text] [Related]
63. Hemorrhagic complications after intravitreal ranibizumab injection for polypoidal choroidal vasculopathy.
Cho HJ; Lee DW; Cho SW; Kim CG; Kim JW
Can J Ophthalmol; 2012 Apr; 47(2):170-5. PubMed ID: 22560424
[TBL] [Abstract][Full Text] [Related]
64. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for polypoidal choroidal vasculopathy.
Sato T; Kishi S; Matsumoto H; Mukai R
Am J Ophthalmol; 2010 Jun; 149(6):947-954.e1. PubMed ID: 20346441
[TBL] [Abstract][Full Text] [Related]
65. SHORT-TERM EFFICACY OF CONBERCEPT AND RANIBIZUMAB FOR POLYPOIDAL CHOROIDAL VASCULOPATHY.
Huang Z; Ding Q; Yan M; Lian H; Chen Z; Chen X; Song Y
Retina; 2019 May; 39(5):889-895. PubMed ID: 29360683
[TBL] [Abstract][Full Text] [Related]
66. Efficacy and Safety of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: A Randomized Clinical Trial.
Koh A; Lai TYY; Takahashi K; Wong TY; Chen LJ; Ruamviboonsuk P; Tan CS; Feller C; Margaron P; Lim TH; Lee WK;
JAMA Ophthalmol; 2017 Nov; 135(11):1206-1213. PubMed ID: 28983556
[TBL] [Abstract][Full Text] [Related]
67. Subfoveal choroidal thickness in polypoidal choroidal vasculopathy after switching to intravitreal aflibercept injection.
Saito M; Kano M; Itagaki K; Ise S; Imaizumi K; Sekiryu T
Jpn J Ophthalmol; 2016 Jan; 60(1):35-41. PubMed ID: 26350229
[TBL] [Abstract][Full Text] [Related]
68. Choroidal thickness changes after intravitreal ranibizumab and photodynamic therapy in recurrent polypoidal choroidal vasculopathy.
Maruko I; Iida T; Oyamada H; Sugano Y; Ojima A; Sekiryu T
Am J Ophthalmol; 2013 Sep; 156(3):548-556. PubMed ID: 23810474
[TBL] [Abstract][Full Text] [Related]
69. Retinal pigment epithelial atrophy over polypoidal choroidal vasculopathy lesions during ranibizumab monotherapy.
Hikichi T; Kitamei H; Shioya S
BMC Ophthalmol; 2016 May; 16(1):55. PubMed ID: 27184489
[TBL] [Abstract][Full Text] [Related]
70. Factors influencing visual outcome of polypoidal choroidal vasculopathy one year after photodynamic therapy.
Mori R; Yuzawa M; Lee Z; Haruyama M; Akaza E
Graefes Arch Clin Exp Ophthalmol; 2010 Sep; 248(9):1233-9. PubMed ID: 20352440
[TBL] [Abstract][Full Text] [Related]
71. Relationship between clinical characteristics of polypoidal choroidal vasculopathy and choroidal vascular hyperpermeability.
Koizumi H; Yamagishi T; Yamazaki T; Kinoshita S
Am J Ophthalmol; 2013 Feb; 155(2):305-313.e1. PubMed ID: 23022162
[TBL] [Abstract][Full Text] [Related]
72. Five-year follow-up results of photodynamic therapy for polypoidal choroidal vasculopathy.
Kang HM; Kim YM; Koh HJ
Am J Ophthalmol; 2013 Mar; 155(3):438-447.e1. PubMed ID: 23218705
[TBL] [Abstract][Full Text] [Related]
73. Prospective evaluation of subretinal vessel location in polypoidal choroidal vasculopathy (PCV) and response of hemorrhagic and exudative PCV to high-dose antiangiogenic therapy (an American Ophthalmological Society thesis).
Kokame GT
Trans Am Ophthalmol Soc; 2014 Jul; 112():74-93. PubMed ID: 25646029
[TBL] [Abstract][Full Text] [Related]
74. Real-World Treatment Outcomes of Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy in Asians.
Fenner BJ; Ting DSW; Tan ACS; Teo K; Chan CM; Mathur R; Yeo IYS; Wong TY; Wong EYM; Cheung CMG
Ophthalmol Retina; 2020 Apr; 4(4):403-414. PubMed ID: 31953109
[TBL] [Abstract][Full Text] [Related]
75. One-year results of reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy.
Yamashita A; Shiraga F; Shiragami C; Ono A; Tenkumo K
Am J Ophthalmol; 2010 Mar; 149(3):465-71.e1. PubMed ID: 20042180
[TBL] [Abstract][Full Text] [Related]
76. Treatment of polypoidal choroidal vasculopathy by intravitreal injection of bevacizumab.
Tsujikawa A; Ooto S; Yamashiro K; Tamura H; Otani A; Yoshimura N
Jpn J Ophthalmol; 2010 Jul; 54(4):310-9. PubMed ID: 20700799
[TBL] [Abstract][Full Text] [Related]
77. Long-term visual outcomes for treatment of submacular haemorrhage secondary to polypoidal choroidal vasculopathy.
Kang HG; Kang H; Byeon SH; Kim SS; Koh HJ; Lee SC; Kim M
Clin Exp Ophthalmol; 2018 Nov; 46(8):916-925. PubMed ID: 29652440
[TBL] [Abstract][Full Text] [Related]
78. Photodynamic therapy with or without intravitreal bevacizumab for polypoidal choroidal vasculopathy: two years of follow-up.
Lee YA; Yang CH; Yang CM; Ho TC; Lin CP; Huang JS; Chen MS
Am J Ophthalmol; 2012 Nov; 154(5):872-880.e2. PubMed ID: 22831838
[TBL] [Abstract][Full Text] [Related]
79. Efficacy of intravitreal bevacizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy.
Gomi F; Sawa M; Wakabayashi T; Sasamoto Y; Suzuki M; Tsujikawa M
Am J Ophthalmol; 2010 Jul; 150(1):48-54.e1. PubMed ID: 20609707
[TBL] [Abstract][Full Text] [Related]
80. Factors predictive of outcomes 1 year after 3 monthly ranibizumab injections and as-needed reinjections for polypoidal choroidal vasculopathy in Japanese patients.
Hikichi T; Higuchi M; Matsushita T; Kosaka S; Matsushita R; Takami K; Ohtsuka H
Retina; 2013 Oct; 33(9):1949-58. PubMed ID: 23612049
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
